EUVIMEDEUVIMED entdecken
Crossref

Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy

Roberto Ravasio, Silvia Antonelli, Veronica Rogai, Walid Fakhouri, Jean Philippe Capron, Serena Losi

Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish · 2018

DOI: 10.1177/2284240318790951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2018. Verfasst von Roberto Ravasio und 5 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Ravasio, R., Antonelli, S., Rogai, V., Fakhouri, W., Capron, J. P., & Losi, S. (2018). Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. https://doi.org/10.1177/2284240318790951

Vancouver

Ravasio R, Antonelli S, Rogai V, Fakhouri W, Capron JP, Losi S. Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 2018. doi:10.1177/2284240318790951

BibTeX
@article{Ravasio2018,
  author = {Ravasio, Roberto and Antonelli, Silvia and Rogai, Veronica and Fakhouri, Walid and Capron, Jean Philippe and Losi, Serena},
  title = {Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy},
  journal = {Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish},
  year = {2018},
  doi = {10.1177/2284240318790951}
}
Kostenlos starten →